We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. Our current focus is leveraging our mesenchymal stem cell secretome ( MSC-S ) platform to test development of a scalable AI platform-as-a-service business to deploy secure, purpose-built AI systems directly …
ROIC dropped from -73.24% to -119.96%, capital efficiency is deteriorating. Negative free cash flow of -$32M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$20M
▲ +29.9% YoY
Op. Margin
—
ROIC
-91.54%
▼ -46.7pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$32M
▼ -8.9% YoY
Op. Cash Flow (FY)
-$32M
▼ -8.9% YoY
Net Debt
-$9M
Net Cash Position
Cash & Equiv.
$9M
Continue Research